COP, CVX, XOM — US-Iran strikes and counter-strikes rattle Middle East all week

The week saw a full escalation cycle: US military struck Iran, Iran's Revolutionary Guards reported retaliatory strikes on US-linked regional targets, and a cargo ship was fired upon in the Strait of Hormuz before a ceasefire-adjacent pause. Oil markets whipsawed as the shipping-lane risk premium spiked and then partially unwound once the Strait remained open.

*Impact:* Energy is a cross-portfolio risk: agents holding energy puts (APA, SLB, BKR, HAL, OXY) have been riding falling crude, but a sustained Hormuz closure would reverse that trade sharply — the cease-fire status is the variable to watch, not the daily headline count.

OpenAI IPO delay spooks AI sentiment; Seoul falls 8% in sympathy

Reports that OpenAI is considering pushing its public offering to 2027 hit risk sentiment hard mid-week. Asian equity markets, already edgy on AI-spending-payoff concerns, amplified the move — Seoul's KOSPI dropped roughly 8% in a single session before partially recovering. The narrative around 'when does AI capex turn into earnings' is now visibly affecting equity risk premia across the sector.

*Impact:* This is the macro backdrop for nearly every held name this week: NVDA, MSFT, GOOGL/GOOG, META, AVGO, MRVL, CSCO all trade against AI-spending confidence, and a prolonged IPO delay would signal that even insiders see the timeline for monetization stretching out.

MSFT, GOOG, GOOGL, META, AMZN, NFLX, CSCO — Trump threatens 100% tariffs on digital-services-tax countries

The Trump administration threatened to impose 100% tariffs on European nations that maintain digital services taxes targeting US tech firms. The move is a direct escalation of the longstanding dispute over how countries tax the revenue of US platform companies operating in their markets, and it raises the prospect of retaliatory EU regulatory tightening — including on AWS, which the EU simultaneously proposed designating as a 'gatekeeper' under the Digital Markets Act.

*Impact:* Several held names sit squarely in the crosshairs: MSFT, GOOGL/GOOG, META, AMZN, and CSCO all have meaningful European revenue; the tariff threat plus the AWS gatekeeper designation create a two-sided regulatory squeeze that agents holding these names fundamentally should track, separate from near-term price noise.

SPCX, NDAQ — SpaceX joins the Nasdaq-100, forcing billions in passive rebalancing

Nasdaq announced that SpaceX (SPCX) will enter the Nasdaq-100 index before the open on July 7. Index inclusion at this scale forces every passive Nasdaq-100 tracker — ETFs, futures, structured products — to buy the name proportionally, generating mechanically predictable demand. The Russell reconstitution the same week set a single-day Nasdaq Closing Cross record of $334 billion.

*Impact:* Agents hold NDAQ on both the long and short side; the index inclusion is a direct revenue event for Nasdaq's licensing and data business, and the record Russell reconstitution volumes are another data point for that same line — modestly supportive for the dip_buyer and options_momentum longs sitting against a put position.

NVDA, AVGO — OpenAI building its own chip with Broadcom, not just buying Nvidia

OpenAI confirmed it is designing a custom AI accelerator in partnership with Broadcom. This is a natural-language model inference chip, not a training chip, and it targets reducing OpenAI's dependence on Nvidia's H-series and B-series GPUs for the highest-volume workloads. Broadcom gains a flagship ASIC customer; Nvidia potentially loses some margin leverage at the margin, though training workloads remain GPU-dominated.

*Impact:* The immutable long in NVDA (entered $219.45, now $192.53, stop $186.53) is within 3% of its stop — this story doesn't change the training-chip thesis but does add a ceiling to inference-market pricing power; for AVGO, dip_buyer_frozen and dip_buyer_peer_aware longs see this as a fundamental positive, adding a named hyperscaler to the custom-silicon pipeline that underpins the $495 targets.

AAPL — Apple lobbies White House to buy chips from blacklisted Chinese firm CXMT

Apple is pressing the Trump administration for clearance to purchase DRAM from ChangXin Memory Technologies, a Chinese company on the Pentagon's entity list. The ask reflects the acute cost pressure Apple is under from soaring memory prices — the same dynamic that forced it to raise iPad and MacBook prices this week, sending shares down before a partial Friday recovery. CXMT approval would give Apple a cheaper alternative to Samsung and SK Hynix.

*Impact:* The immutable long (entered $292.75, now $283.78, stop $248.84) has room before the stop but the hardware-cost story is structural; approval of the CXMT waiver would be a material margin tailwind, while denial leaves Apple stuck paying premium DRAM prices through at least 2027 — worth watching as a binary regulatory outcome.

GOOGL, GOOG — Alphabet bleeds senior Gemini and DeepMind talent to rivals

Within a single week, several core Gemini contributors — Jonas Adler, Alexander Pritzel — defected to Anthropic, joining earlier departures of Noam Shazeer (to OpenAI) and John Jumper (to Anthropic). These are research scientists who were central to both the Gemini model and DeepMind's protein-structure work. The clustering of exits in days is unusual and suggests either compensation or strategic-direction friction inside Alphabet's AI division.

*Impact:* Both dip_buyer_frozen and immutable longs in GOOGL/GOOG are underwater (entries $362.97 and $388.60 vs. ~$336 current) and the stops at $330–333 are close; talent attrition at this seniority level is a genuine risk to Gemini's competitive roadmap, though Bernstein's Q1 data calling Google Cloud the leading AI platform by incremental revenue is the offsetting fundamental argument.

AAPL, MSFT — Micron blowout quarter spotlights memory cost surge hitting Apple and Microsoft

Micron's fiscal Q3 results were exceptional on the supply side — AI customers rushing to secure HBM and high-density DRAM pushed Micron's margins sharply higher. The flip side is that the same memory shortage is a cost headwind for buyers: Apple cited it explicitly for its price hikes, and Microsoft's hardware and cloud infrastructure costs are exposed to the same dynamic.

*Impact:* For MSFT (dip_buyer_peer_aware long, entered $367.18, now $371.36, target $466.32), elevated memory costs compress data-center margin in the near term — not a thesis-changer for a $466 target but worth noting as a Q2 earnings watch item; AAPL's immutable long is more directly pressured since hardware gross margin is the immediate victim.

GILD — Gilead wins first-line Trodelvy approval in US and Europe simultaneously

The FDA approved Trodelvy (sacituzumab govitecan) as a first-line treatment for metastatic triple-negative breast cancer, with European regulators granting a parallel approval. First-line status is a step-change in addressable population — it replaces chemotherapy in newly diagnosed patients rather than waiting for treatment failure. NCCN guideline endorsement was simultaneous, which accelerates formulary uptake.

*Impact:* The dip_buyer_frozen long (entered $123.69, now $127.66, target $137.50) is working as intended — this approval is the kind of pipeline catalyst the entry thesis would have anticipated; the simultaneous US/EU decision reduces geographic concentration risk and moves the position meaningfully toward its $137.50 target.

MRNA — Moderna surges nearly 13% after investor day pipeline showcase

Moderna held an investor event that highlighted its late-stage pipeline — not just updated COVID shots but oncology mRNA candidates and RSV and flu combination vaccines. The stock jumped about 13% to its highest level since 2024, driven by renewed confidence that the company's post-COVID revenue transition is executable. No single drug approval drove the move; it was a portfolio narrative reset.

*Impact:* The sir_pv long (entered $55.38, now $67.29, target $66.46) has already exceeded its stated target — the position is effectively at decision time on whether to ride further or take the gain; the investor-day catalyst is exactly the kind of non-recurring event that can pull forward price, which is useful context for any stop or target reassessment.

ABBV — Abbvie wins FDA pediatric approval expanding Skyrizi's label

The FDA approved Skyrizi (risankizumab) for children six and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis, including a new 55 mg pre-filled syringe for weight-based dosing. Pediatric label expansions carry market exclusivity incentives and open a new patient cohort for Abbvie's fastest-growing drug.

*Impact:* The sir_pv long (entered $229.96, now $251.64, target $275.95) continues to build toward its target; Skyrizi label breadth is a key part of the bull case for AbbVie's post-Humira revenue replacement, and pediatric approvals typically add durable incremental volume rather than one-time bumps.

IBM — IBM unveils sub-1nm chip and standalone quantum foundry Anderon

IBM announced a semiconductor breakthrough using a new nanostack architecture to achieve a sub-1 nanometer chip — an industry first by its characterization. Separately, it unveiled Anderon, a standalone quantum wafer foundry focused on commercial quantum chip manufacturing in the US. Both announcements are R&D stage but signal IBM's strategy to monetize advanced semiconductor and quantum IP beyond traditional services revenue.

*Impact:* The dip_buyer_peer_aware and dip_buyer_frozen longs (entered ~$249–263, now $271.40, target $332.46) are in the money; the announcements reinforce the hardware-plus-quantum narrative that differentiates IBM from pure-play IT services peers, which is consistent with the fundamental thesis both agents used to enter.

NKE — Nike earnings Tuesday; Keybanc downgrade adds pressure to put position

Keybanc downgraded Nike this week, citing continued market share erosion and margin uncertainty heading into Tuesday's quarterly report. Nike has fallen roughly 12% since early June on a combination of tariff-related cost concerns and sluggish North America trends. The earnings print will be the largest near-term catalyst for the stock.

*Impact:* The options_momentum put ($43 strike, July 24 expiry, entered at $1.92, now $2.64, target $3.85) is well-positioned ahead of the report — the Keybanc cut adds fundamental weight to the bearish setup, though a relief rally on any positive guidance revision would work against the position given only four weeks of remaining time value.

MRVL — Marvell secures Nvidia equity deal and acquires two AI connectivity firms

Marvell agreed to issue equity to Nvidia as part of a deepened AI data-center collaboration, and separately announced acquisitions of Celestial AI (optical interconnect) and XConn Technologies (custom silicon connectivity). Jensen Huang publicly endorsed Marvell as a hyperscale partner. Taken together, the moves position Marvell as the go-to ASIC and connectivity layer for AI infrastructure customers who want alternatives to vertical GPU stacks.

*Impact:* The dip_buyer_frozen long (entered $266.88, now $266.13, target $324.20) is essentially flat on entry; the Nvidia equity stake is an unusual vote of confidence that strengthens the bull case for the $324 target, though a Seeking Alpha downgrade to hold this week reflects concern that the good news is now priced in — worth monitoring whether the technical picture confirms the fundamental thesis.

LEN — Housing affordability bill passes Congress, homebuilder stocks post best day in a year

Congress passed what analysts described as the most sweeping housing affordability legislation in decades, addressing zoning reform, construction financing, and first-time buyer incentives. The iShares US Home Construction ETF jumped roughly 6.3% on the news — its sharpest single-day gain since July 2025 — as markets priced in a structural demand unlock for new construction.

*Impact:* Lennar longs across dip_buyer_peer_aware (entered $85.22, target $97.94), sir_pv (entered $92.55, target $111.06), and dip_buyer_evolving (entered $85.13) all benefited from the move; LEN at $93.53 now sits within a few percent of the $97.94 target on the shorter-term positions, making the legislative catalyst a potential partial-exit marker rather than just a sentiment boost.